Use of U-500 Regular Insulin via Continuous Subcutaneous Insulin Infusion: Clinical Practice Experience

Davidson MB Navar MD Echeverry D Duran P . U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients. Diabetes Care. 2010; 33 (2): 281–3.

Nayyar V Lawrence IG Kong MF Gallagher A. Gregory R Hiles S Jackson S McNally P Davies MJ . Long-term follow-up of patietns on U-500 Human Actrapid in Leicestershire. Diabetologia. 2007; 50 (Suppl 1): S395.

Lane WS Weinrib SL Rappaport JM Przestrzelski T . A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract. 2010; 16 (5): 778–84.

Bulchandani DG Konrady T Hamburg MS . Clinical efficacy and patient satisfaction with U-500 insulin pump therapy in patients with type 2 diabetes. Endocr Pract. 2007; 13 (7): 721–5.

Knee TS Seidensticker DF Walton JL Solberg LM Lasseter DH . A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract. 2003; 9 (3): 181–6.

Lane WS Cochran EK Jackson JA Scism-Bacon JL Corey IB Hirsch IB Skyler JS . High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009; 15 (1): 71–9.